TY - JOUR AU - Huggins, C. AU - Hodges, C. V. PY - 2002 DA - 2002// TI - Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 JO - J Urol VL - 167 ID - Huggins2002 ER - TY - JOUR AU - Scher, H. I. AU - Halabi, S. AU - Tannock, I. AU - Morris, M. AU - Sternberg, C. N. AU - Carducci, M. A. PY - 2008 DA - 2008// TI - Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group JO - J Clin Oncol VL - 26 ID - Scher2008 ER - TY - STD TI - Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ: The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). In: American Society Of Clinical Oncology Annual Meeting: 2015; Chicago, IL ID - ref3 ER - TY - JOUR AU - Scher, H. I. AU - Sawyers, C. L. PY - 2005 DA - 2005// TI - Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis JO - J Clin Oncol VL - 23 ID - Scher2005 ER - TY - JOUR AU - Beer, T. M. AU - Armstrong, A. J. AU - Rathkopf, D. E. AU - Loriot, Y. AU - Sternberg, C. N. AU - Higano, C. S. PY - 2014 DA - 2014// TI - Enzalutamide in metastatic prostate cancer before chemotherapy JO - N Engl J Med VL - 371 ID - Beer2014 ER - TY - JOUR AU - Bono, J. S. AU - Logothetis, C. J. AU - Molina, A. AU - Fizazi, K. AU - North, S. AU - Chu, L. PY - 2011 DA - 2011// TI - Abiraterone and increased survival in metastatic prostate cancer JO - N Engl J Med VL - 364 ID - Bono2011 ER - TY - JOUR AU - Ryan, C. J. AU - Smith, M. R. AU - Bono, J. S. AU - Molina, A. AU - Logothetis, C. J. AU - Souza, P. PY - 2013 DA - 2013// TI - Abiraterone in metastatic prostate cancer without previous chemotherapy JO - N Engl J Med VL - 368 ID - Ryan2013 ER - TY - JOUR AU - Scher, H. I. AU - Fizazi, K. AU - Saad, F. AU - Taplin, M. E. AU - Sternberg, C. N. AU - Miller, K. PY - 2012 DA - 2012// TI - Increased survival with enzalutamide in prostate cancer after chemotherapy JO - N Engl J Med VL - 367 ID - Scher2012 ER - TY - JOUR AU - Antonarakis, E. S. AU - Lu, C. AU - Wang, H. AU - Luber, B. AU - Nakazawa, M. AU - Roeser, J. C. PY - 2014 DA - 2014// TI - AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer JO - N Engl J Med VL - 371 ID - Antonarakis2014 ER - TY - JOUR AU - Asangani, I. A. AU - Dommeti, V. L. AU - Wang, X. AU - Malik, R. AU - Cieslik, M. AU - Yang, R. PY - 2014 DA - 2014// TI - Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer JO - Nature VL - 510 ID - Asangani2014 ER - TY - JOUR AU - Carreira, S. AU - Romanel, A. AU - Goodall, J. AU - Grist, E. AU - Ferraldeschi, R. AU - Miranda, S. PY - 2014 DA - 2014// TI - Tumor clone dynamics in lethal prostate cancer JO - Sci Transl Med VL - 6 ID - Carreira2014 ER - TY - JOUR AU - Chang, K. H. AU - Li, R. AU - Kuri, B. AU - Lotan, Y. AU - Roehrborn, C. G. AU - Liu, J. PY - 2013 DA - 2013// TI - A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer JO - Cell VL - 154 ID - Chang2013 ER - TY - JOUR AU - Chen, C. D. AU - Welsbie, D. S. AU - Tran, C. AU - Baek, S. H. AU - Chen, R. AU - Vessella, R. PY - 2004 DA - 2004// TI - Molecular determinants of resistance to antiandrogen therapy JO - Nat Med VL - 10 ID - Chen2004 ER - TY - JOUR AU - Cho, E. AU - Montgomery, R. B. AU - Mostaghel, E. A. PY - 2014 DA - 2014// TI - Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression JO - Endocrinology VL - 155 ID - Cho2014 ER - TY - JOUR AU - Drake, J. M. AU - Graham, N. A. AU - Lee, J. K. AU - Stoyanova, T. AU - Faltermeier, C. M. AU - Sud, S. PY - 2013 DA - 2013// TI - Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets JO - Proc Natl Acad Sci U S A VL - 110 ID - Drake2013 ER - TY - JOUR AU - Evaul, K. AU - Li, R. AU - Papari-Zareei, M. AU - Auchus, R. J. AU - Sharifi, N. PY - 2010 DA - 2010// TI - 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer JO - Endocrinology VL - 151 ID - Evaul2010 ER - TY - JOUR AU - Li, Z. AU - Bishop, A. C. AU - Alyamani, M. AU - Garcia, J. A. AU - Dreicer, R. AU - Bunch, D. PY - 2015 DA - 2015// TI - Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer JO - Nature VL - 523 ID - Li2015 ER - TY - JOUR AU - Malik, R. AU - Khan, A. P. AU - Asangani, I. A. AU - Cieslik, M. AU - Prensner, J. R. AU - Wang, X. PY - 2015 DA - 2015// TI - Targeting the MLL complex in castration-resistant prostate cancer JO - Nat Med VL - 21 ID - Malik2015 ER - TY - JOUR AU - Montgomery, R. B. AU - Mostaghel, E. A. AU - Vessella, R. AU - Hess, D. L. AU - Kalhorn, T. F. AU - Higano, C. S. PY - 2008 DA - 2008// TI - Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth JO - Cancer Res VL - 68 ID - Montgomery2008 ER - TY - JOUR AU - Mostaghel, E. A. AU - Marck, B. T. AU - Plymate, S. R. AU - Vessella, R. L. AU - Balk, S. AU - Matsumoto, A. M. PY - 2011 DA - 2011// TI - Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants JO - Clin Cancer Res VL - 17 ID - Mostaghel2011 ER - TY - JOUR AU - Mostaghel, E. A. AU - Solomon, K. R. AU - Pelton, K. AU - Freeman, M. R. AU - Montgomery, R. B. PY - 2012 DA - 2012// TI - Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors JO - PLoS One VL - 7 ID - Mostaghel2012 ER - TY - JOUR AU - Wright, J. L. AU - Kwon, E. M. AU - Ostrander, E. A. AU - Montgomery, R. B. AU - Lin, D. W. AU - Vessella, R. PY - 2011 DA - 2011// TI - Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes JO - Cancer Epidemiol Biomarkers Prev VL - 20 ID - Wright2011 ER - TY - JOUR AU - Yang, M. AU - Xie, W. AU - Mostaghel, E. AU - Nakabayashi, M. AU - Werner, L. AU - Sun, T. PY - 2011 DA - 2011// TI - SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer JO - J Clin Oncol VL - 29 ID - Yang2011 ER - TY - JOUR AU - Yeh, S. AU - Lin, H. K. AU - Kang, H. Y. AU - Thin, T. H. AU - Lin, M. F. AU - Chang, C. PY - 1999 DA - 1999// TI - From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells JO - Proc Natl Acad Sci U S A VL - 96 ID - Yeh1999 ER - TY - JOUR AU - Yu, Z. AU - Chen, S. AU - Sowalsky, A. G. AU - Voznesensky, O. S. AU - Mostaghel, E. A. AU - Nelson, P. S. PY - 2014 DA - 2014// TI - Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer JO - Clin Cancer Res VL - 20 ID - Yu2014 ER - TY - JOUR AU - Tan, M. H. AU - Li, J. AU - Xu, H. E. AU - Melcher, K. AU - Yong, E. L. PY - 2015 DA - 2015// TI - Androgen receptor: structure, role in prostate cancer and drug discovery JO - Acta Pharmacol Sin VL - 36 ID - Tan2015 ER - TY - JOUR AU - Lu, C. AU - Luo, J. PY - 2013 DA - 2013// TI - Decoding the androgen receptor splice variants JO - Transl Andrology Urol VL - 2 ID - Lu2013 ER - TY - JOUR AU - Koryakina, Y. AU - Ta, H. Q. AU - Gioeli, D. PY - 2014 DA - 2014// TI - Androgen receptor phosphorylation: biological context and functional consequences JO - Endocr Relat Cancer VL - 21 ID - Koryakina2014 ER - TY - JOUR AU - Garraway, L. A. AU - Sellers, W. R. PY - 2006 DA - 2006// TI - Lineage dependency and lineage-survival oncogenes in human cancer JO - Nat Rev Cancer VL - 6 ID - Garraway2006 ER - TY - JOUR AU - Nelson, P. S. PY - 2012 DA - 2012// TI - Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer JO - J Clin Oncol VL - 30 ID - Nelson2012 ER - TY - JOUR AU - Robinson, D. AU - Allen, E. M. AU - Wu, Y. M. AU - Schultz, N. AU - Lonigro, R. J. AU - Mosquera, J. M. PY - 2015 DA - 2015// TI - Integrative clinical genomics of advanced prostate cancer JO - Cell VL - 161 ID - Robinson2015 ER - TY - JOUR AU - Ryan, C. J. AU - Smith, M. R. AU - Fizazi, K. AU - Saad, F. AU - Mulders, P. F. AU - Sternberg, C. N. PY - 2015 DA - 2015// TI - Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study JO - Lancet Oncol VL - 16 ID - Ryan2015 ER - TY - JOUR AU - Salvi, S. AU - Casadio, V. AU - Conteduca, V. AU - Burgio, S. L. AU - Menna, C. AU - Bianchi, E. PY - 2015 DA - 2015// TI - Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone JO - Br J Cancer VL - 112 ID - Salvi2015 ER - TY - JOUR AU - Azad, A. A. AU - Volik, S. V. AU - Wyatt, A. W. AU - Haegert, A. AU - Bihan, S. AU - Bell, R. H. PY - 2015 DA - 2015// TI - Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer JO - Clin Cancer Res VL - 21 ID - Azad2015 ER - TY - JOUR AU - Tamae, D. AU - Mostaghel, E. AU - Montgomery, B. AU - Nelson, P. S. AU - Balk, S. P. AU - Kantoff, P. W. PY - 2015 DA - 2015// TI - The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer JO - Chem Biol Interact VL - 234 ID - Tamae2015 ER - TY - JOUR AU - Taplin, M. E. AU - Montgomery, B. AU - Logothetis, C. J. AU - Bubley, G. J. AU - Richie, J. P. AU - Dalkin, B. L. PY - 2014 DA - 2014// TI - Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study JO - J Clin Oncol VL - 32 ID - Taplin2014 ER - TY - JOUR AU - Shah, R. B. AU - Mehra, R. AU - Chinnaiyan, A. M. AU - Shen, R. AU - Ghosh, D. AU - Zhou, M. PY - 2004 DA - 2004// TI - Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program JO - Cancer Res VL - 64 ID - Shah2004 ER - TY - JOUR AU - Mostaghel, E. A. AU - Morgan, A. AU - Zhang, X. AU - Marck, B. T. AU - Xia, J. AU - Hunter-Merrill, R. PY - 2014 DA - 2014// TI - Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis JO - PLoS One VL - 9 ID - Mostaghel2014 ER - TY - JOUR AU - Mostaghel, E. A. AU - Page, S. T. AU - Lin, D. W. AU - Fazli, L. AU - Coleman, I. M. AU - True, L. D. PY - 2007 DA - 2007// TI - Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer JO - Cancer Res VL - 67 ID - Mostaghel2007 ER - TY - JOUR AU - Titus, M. A. AU - Schell, M. J. AU - Lih, F. B. AU - Tomer, K. B. AU - Mohler, J. L. PY - 2005 DA - 2005// TI - Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer JO - Clin Cancer Res VL - 11 ID - Titus2005 ER - TY - JOUR AU - Liu, C. AU - Lou, W. AU - Zhu, Y. AU - Yang, J. C. AU - Natiminty, N. AU - Gaikwad, N. PY - 2015 DA - 2015// TI - Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer JO - Cancer Res VL - 75 ID - Liu2015 ER - TY - JOUR AU - Cai, C. AU - Chen, S. AU - Ng, P. AU - Bubley, G. J. AU - Nelson, P. S. AU - Mostaghel, E. A. PY - 2011 DA - 2011// TI - Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors JO - Cancer Res VL - 71 ID - Cai2011 ER - TY - JOUR AU - Desmond, J. C. AU - Mountford, J. C. AU - Drayson, M. T. AU - Walker, E. A. AU - Hewison, M. AU - Ride, J. P. PY - 2003 DA - 2003// TI - The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs JO - Cancer Res VL - 63 ID - Desmond2003 ER - TY - JOUR AU - Liedtke, A. J. AU - Adeniji, A. O. AU - Chen, M. AU - Byrns, M. C. AU - Jin, Y. AU - Christianson, D. W. PY - 2013 DA - 2013// TI - Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer JO - J Med Chem VL - 56 ID - Liedtke2013 ER - TY - JOUR AU - Sharifi, N. PY - 2013 DA - 2013// TI - Mechanisms of androgen receptor activation in castration-resistant prostate cancer JO - Endocrinology VL - 154 ID - Sharifi2013 ER - TY - JOUR AU - Hamada, A. AU - Sissung, T. AU - Price, D. K. AU - Danesi, R. AU - Chau, C. H. AU - Sharifi, N. PY - 2008 DA - 2008// TI - Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer JO - Clin Cancer Res VL - 14 ID - Hamada2008 ER - TY - JOUR AU - Sharifi, N. AU - Hamada, A. AU - Sissung, T. AU - Danesi, R. AU - Venzon, D. AU - Baum, C. PY - 2008 DA - 2008// TI - A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer JO - BJU Int VL - 102 ID - Sharifi2008 ER - TY - STD TI - Kantoff PW, Wang X, Xie W, Nakabayashi M, Pomerantz M, Lee GM: Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer. In: Genitourinary Cancers Symposium: 2015; Orlando, FL. ID - ref48 ER - TY - STD TI - Mostaghel EA, Wright JL, Kwon EM, Montgomery RB, Ostrander EA, Vessella R, Nelson P, Stanford JL: Genetic variation in SLCO2B1, SLCO1B3, and prostate cancer risk and mortality. In: Genitourinary Cancers Symposium: 2010; San Francisco, CA. ID - ref49 ER - TY - JOUR AU - Harshman, L. C. AU - Wang, X. AU - Nakabayashi, M. AU - Xie, W. AU - Valenca, L. AU - Werner, L. PY - 2015 DA - 2015// TI - Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer JO - JAMA Oncol VL - 1 ID - Harshman2015 ER - TY - JOUR AU - Ramos, J. D. AU - Yu, E. Y. PY - 2015 DA - 2015// TI - Progress in understanding what is being statin(ed) in prostate cancer JO - JAMA Oncol VL - 1 ID - Ramos2015 ER - TY - JOUR AU - Hu, R. AU - Denmeade, S. R. AU - Luo, J. PY - 2010 DA - 2010// TI - Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer JO - Expert Rev Endocrinol Metab VL - 5 ID - Hu2010 ER - TY - JOUR AU - Dehm, S. M. AU - Schmidt, L. J. AU - Heemers, H. V. AU - Vessella, R. L. AU - Tindall, D. J. PY - 2008 DA - 2008// TI - Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance JO - Cancer Res VL - 68 ID - Dehm2008 ER - TY - JOUR AU - Hu, R. AU - Dunn, T. A. AU - Wei, S. AU - Isharwal, S. AU - Veltri, R. W. AU - Humphreys, E. PY - 2009 DA - 2009// TI - Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer JO - Cancer Res VL - 69 ID - Hu2009 ER - TY - JOUR AU - Sun, S. AU - Sprenger, C. C. AU - Vessella, R. L. AU - Haugk, K. AU - Soriano, K. AU - Mostaghel, E. A. PY - 2010 DA - 2010// TI - Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant JO - J Clin Invest VL - 120 ID - Sun2010 ER - TY - JOUR AU - Nadiminty, N. AU - Tummala, R. AU - Liu, C. AU - Yang, J. AU - Lou, W. AU - Evans, C. P. PY - 2013 DA - 2013// TI - NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants JO - Mol Cancer Ther VL - 12 ID - Nadiminty2013 ER - TY - JOUR AU - Sharifi, N. PY - 2014 DA - 2014// TI - Steroid receptors aplenty in prostate cancer JO - N Engl J Med VL - 370 ID - Sharifi2014 ER - TY - JOUR AU - Arora, V. K. AU - Schenkein, E. AU - Murali, R. AU - Subudhi, S. K. AU - Wongvipat, J. AU - Balbas, M. D. PY - 2013 DA - 2013// TI - Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade JO - Cell VL - 155 ID - Arora2013 ER - TY - JOUR AU - Isikbay, M. AU - Otto, K. AU - Kregel, S. AU - Kach, J. AU - Cai, Y. AU - Vander Griend, D. J. PY - 2014 DA - 2014// TI - Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer JO - Horm Cancer VL - 5 ID - Isikbay2014 ER - TY - STD TI - Efstathiou E, Troncoso P, Tapia EM, Davis JW, Titus MA, Hoang A, Prokhorova IN, Wen S, Logothetis CJ: Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). In: American Society of Clinical Oncology Annual Meeting: 2015; Chicago, IL. ID - ref60 ER - TY - JOUR AU - Fenton, M. A. AU - Shuster, T. D. AU - Fertig, A. M. AU - Taplin, M. E. AU - Kolvenbag, G. AU - Bubley, G. J. PY - 1997 DA - 1997// TI - Functional characterization of mutant androgen receptors from androgen-independent prostate cancer JO - Clin Cancer Res VL - 3 ID - Fenton1997 ER - TY - JOUR AU - Taplin, M. E. AU - Bubley, G. J. AU - Ko, Y. J. AU - Small, E. J. AU - Upton, M. AU - Rajeshkumar, B. PY - 1999 DA - 1999// TI - Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist JO - Cancer Res VL - 59 ID - Taplin1999 ER - TY - JOUR AU - Hara, T. AU - Miyazaki, J. AU - Araki, H. AU - Yamaoka, M. AU - Kanzaki, N. AU - Kusaka, M. PY - 2003 DA - 2003// TI - Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome JO - Cancer Res VL - 63 ID - Hara2003 ER - TY - JOUR AU - Joseph, J. D. AU - Lu, N. AU - Qian, J. AU - Sensintaffar, J. AU - Shao, G. AU - Brigham, D. PY - 2013 DA - 2013// TI - A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 JO - Cancer Discov VL - 3 ID - Joseph2013 ER - TY - JOUR AU - Korpal, M. AU - Korn, J. M. AU - Gao, X. AU - Rakiec, D. P. AU - Ruddy, D. A. AU - Doshi, S. PY - 2013 DA - 2013// TI - An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) JO - Cancer Discov VL - 3 ID - Korpal2013 ER - TY - JOUR AU - Balbas, M. D. AU - Evans, M. J. AU - Hosfield, D. J. AU - Wongvipat, J. AU - Arora, V. K. AU - Watson, P. A. PY - 2013 DA - 2013// TI - Overcoming mutation-based resistance to antiandrogens with rational drug design JO - eLife VL - 2 ID - Balbas2013 ER - TY - JOUR AU - Moilanen, A. M. AU - Riikonen, R. AU - Oksala, R. AU - Ravanti, L. AU - Aho, E. AU - Wohlfahrt, G. PY - 2015 DA - 2015// TI - Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies JO - Sci Rep VL - 5 ID - Moilanen2015 ER - TY - JOUR AU - Fizazi, K. AU - Massard, C. AU - Bono, P. AU - Jones, R. AU - Kataja, V. AU - James, N. PY - 2014 DA - 2014// TI - Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial JO - Lancet Oncol VL - 15 ID - Fizazi2014 ER - TY - JOUR AU - Guo, Z. AU - Yang, X. AU - Sun, F. AU - Jiang, R. AU - Linn, D. E. AU - Chen, H. PY - 2009 DA - 2009// TI - A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth JO - Cancer Res VL - 69 ID - Guo2009 ER - TY - JOUR AU - Hu, R. AU - Lu, C. AU - Mostaghel, E. A. AU - Yegnasubramanian, S. AU - Gurel, M. AU - Tannahill, C. PY - 2012 DA - 2012// TI - Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer JO - Cancer Res VL - 72 ID - Hu2012 ER - TY - JOUR AU - Antonarakis, E. S. AU - Lu, C. AU - Luber, B. AU - Wang, H. AU - Chen, Y. AU - Nakazawa, M. PY - 2015 DA - 2015// TI - Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer JO - JAMA Oncol VL - 1 ID - Antonarakis2015 ER - TY - STD TI - Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ: Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015, [Epub ahead of print] ID - ref72 ER - TY - JOUR AU - Gelmann, E. P. PY - 2002 DA - 2002// TI - Molecular biology of the androgen receptor JO - J Clin Oncol VL - 20 ID - Gelmann2002 ER - TY - STD TI - Montgomery RB, Antonarakis ES, Hussain M, Fizazi K, Joshua AM, Attard G, Sadar M, Perabo F, Chi KN: A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. In: American Society of Clinical Oncology Annual Meeting: 2015; Chicago, IL. ID - ref74 ER - TY - JOUR AU - Yu, Z. AU - Cai, C. AU - Gao, S. AU - Simon, N. I. AU - Shen, H. C. AU - Balk, S. P. PY - 2014 DA - 2014// TI - Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor JO - Clin Cancer Res VL - 20 ID - Yu2014 ER - TY - JOUR AU - Njar, V. C. AU - Brodie, A. M. PY - 2015 DA - 2015// TI - Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer JO - J Med Chem VL - 58 ID - Njar2015 ER - TY - JOUR AU - Liu, C. AU - Lou, W. AU - Zhu, Y. AU - Nadiminty, N. AU - Schwartz, C. T. AU - Evans, C. P. PY - 2014 DA - 2014// TI - Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer JO - Clin Cancer Res VL - 20 ID - Liu2014 ER - TY - JOUR AU - Schweizer, M. T. AU - Antonarakis, E. S. AU - Wang, H. AU - Ajiboye, A. S. AU - Spitz, A. AU - Cao, H. PY - 2015 DA - 2015// TI - Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study JO - Sci Transl Med VL - 7 ID - Schweizer2015 ER - TY - JOUR AU - Dehm, S. M. AU - Tindall, D. J. PY - 2007 DA - 2007// TI - Androgen receptor structural and functional elements: role and regulation in prostate cancer JO - Mol Endocrinol VL - 21 ID - Dehm2007 ER - TY - JOUR AU - Myung, J. K. AU - Banuelos, C. A. AU - Fernandez, J. G. AU - Mawji, N. R. AU - Wang, J. AU - Tien, A. H. PY - 2013 DA - 2013// TI - An androgen receptor N-terminal domain antagonist for treating prostate cancer JO - J Clin Invest VL - 123 ID - Myung2013 ER - TY - JOUR AU - Brand, L. J. AU - Olson, M. E. AU - Ravindranathan, P. AU - Guo, H. AU - Kempema, A. M. AU - Andrews, T. E. PY - 2015 DA - 2015// TI - EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer JO - Oncotarget VL - 6 ID - Brand2015 ER - TY - JOUR AU - Shang, Y. AU - Myers, M. AU - Brown, M. PY - 2002 DA - 2002// TI - Formation of the androgen receptor transcription complex JO - Mol Cell VL - 9 ID - Shang2002 ER - TY - JOUR AU - Grasso, C. S. AU - Wu, Y. M. AU - Robinson, D. R. AU - Cao, X. AU - Dhanasekaran, S. M. AU - Khan, A. P. PY - 2012 DA - 2012// TI - The mutational landscape of lethal castration-resistant prostate cancer JO - Nature VL - 487 ID - Grasso2012 ER - TY - JOUR AU - Welsbie, D. S. AU - Xu, J. AU - Chen, Y. AU - Borsu, L. AU - Scher, H. I. AU - Rosen, N. PY - 2009 DA - 2009// TI - Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer JO - Cancer Res VL - 69 ID - Welsbie2009 ER - TY - JOUR AU - Molife, L. R. AU - Attard, G. AU - Fong, P. C. AU - Karavasilis, V. AU - Reid, A. H. AU - Patterson, S. PY - 2010 DA - 2010// TI - Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) JO - Ann Oncol VL - 21 ID - Molife2010 ER - TY - STD TI - Montgomery RB, Eisenberger MA, Heath EI, Sartor AO, Chu F, Shore ND, Edenfield WJ, Koletsky AJ, Lipsitz DU, Cochran JS, Nordquist LT, Roberts J, Taplin ME: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study. In: American Society of Clinical Oncology Annual Meeting: 2014; Chicago, IL. ID - ref86 ER - TY - STD TI - Roberts J, Dhillon R, Dransfield DT, Mamlouk KK, Ferrante KJ: Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC). In: Genitourinary Cancers Symposium: 2015; Orlando, FL. ID - ref87 ER - TY - JOUR AU - Andrews, P. AU - Thyssen, J. AU - Lorke, D. PY - 1982 DA - 1982// TI - The biology and toxicology of molluscicides, Bayluscide JO - Pharmacol Ther VL - 19 ID - Andrews1982 ER - TY - JOUR AU - Loriot, Y. AU - Bianchini, D. AU - Ileana, E. AU - Sandhu, S. AU - Patrikidou, A. AU - Pezaro, C. PY - 2013 DA - 2013// TI - Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) JO - Ann Oncol VL - 24 ID - Loriot2013 ER - TY - JOUR AU - Noonan, K. L. AU - North, S. AU - Bitting, R. L. AU - Armstrong, A. J. AU - Ellard, S. L. AU - Chi, K. N. PY - 2013 DA - 2013// TI - Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide JO - Ann Oncol VL - 24 ID - Noonan2013 ER - TY - JOUR AU - Schrader, A. J. AU - Boegemann, M. AU - Ohlmann, C. H. AU - Schnoeller, T. J. AU - Krabbe, L. M. AU - Hajili, T. PY - 2014 DA - 2014// TI - Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone JO - Eur Urol VL - 65 ID - Schrader2014 ER - TY - JOUR AU - Bianchini, D. AU - Lorente, D. AU - Rodriguez-Vida, A. AU - Omlin, A. AU - Pezaro, C. AU - Ferraldeschi, R. PY - 2014 DA - 2014// TI - Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone JO - Eur J Cancer VL - 50 ID - Bianchini2014 ER - TY - JOUR AU - Suzman, D. L. AU - Luber, B. AU - Schweizer, M. T. AU - Nadal, R. AU - Antonarakis, E. S. PY - 2014 DA - 2014// TI - Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone JO - Prostate VL - 74 ID - Suzman2014 ER - TY - JOUR AU - Badrising, S. AU - Noort, V. AU - Oort, I. M. AU - Berg, H. P. AU - Los, M. AU - Hamberg, P. PY - 2014 DA - 2014// TI - Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment JO - Cancer VL - 120 ID - Badrising2014 ER - TY - JOUR AU - Cheng, H. H. AU - Gulati, R. AU - Azad, A. AU - Nadal, R. AU - Twardowski, P. AU - Vaishampayan, U. N. PY - 2015 DA - 2015// TI - Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel JO - Prostate Cancer Prostatic Dis VL - 18 ID - Cheng2015 ER - TY - JOUR AU - Azad, A. A. AU - Eigl, B. J. AU - Murray, R. N. AU - Kollmannsberger, C. AU - Chi, K. N. PY - 2015 DA - 2015// TI - Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients JO - Eur Urol VL - 67 ID - Azad2015 ER - TY - JOUR AU - Taplin, M. E. AU - Manola, J. AU - Oh, W. K. AU - Kantoff, P. W. AU - Bubley, G. J. AU - Smith, M. PY - 2008 DA - 2008// TI - A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones JO - BJU Int VL - 101 ID - Taplin2008 ER - TY - JOUR AU - Lonergan, P. E. AU - Tindall, D. J. PY - 2011 DA - 2011// TI - Androgen receptor signaling in prostate cancer development and progression JO - J Carcinogenesis VL - 10 ID - Lonergan2011 ER - TY - JOUR AU - Wang, Y. AU - Mikhailova, M. AU - Bose, S. AU - Pan, C. X. AU - deVere White, R. W. AU - Ghosh, P. M. PY - 2008 DA - 2008// TI - Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival JO - Oncogene VL - 27 ID - Wang2008 ER - TY - JOUR AU - Li, Y. AU - Wang, Z. AU - Kong, D. AU - Li, R. AU - Sarkar, S. H. AU - Sarkar, F. H. PY - 2008 DA - 2008// TI - Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells JO - J Biol Chem VL - 283 ID - Li2008 ER - TY - JOUR AU - Bitting, R. L. AU - Armstrong, A. J. PY - 2013 DA - 2013// TI - Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer JO - Endocr Relat Cancer VL - 20 ID - Bitting2013 ER - TY - JOUR AU - Carver, B. S. AU - Chapinski, C. AU - Wongvipat, J. AU - Hieronymus, H. AU - Chen, Y. AU - Chandarlapaty, S. PY - 2011 DA - 2011// TI - Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer JO - Cancer Cell VL - 19 ID - Carver2011 ER - TY - JOUR AU - Gao, J. AU - Aksoy, B. A. AU - Dogrusoz, U. AU - Dresdner, G. AU - Gross, B. AU - Sumer, S. O. PY - 2013 DA - 2013// TI - Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal JO - Sci Signal VL - 6 ID - Gao2013 ER - TY - JOUR AU - Cerami, E. AU - Gao, J. AU - Dogrusoz, U. AU - Gross, B. E. AU - Sumer, S. O. AU - Aksoy, B. A. PY - 2012 DA - 2012// TI - The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data JO - Cancer Discov VL - 2 ID - Cerami2012 ER - TY - STD TI - Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical reviews in oncology/hematology 2015, doi: 10.1016/j.critrevonc.2015.07.005. ID - ref105 ER - TY - JOUR AU - Hsieh, A. C. AU - Liu, Y. AU - Edlind, M. P. AU - Ingolia, N. T. AU - Janes, M. R. AU - Sher, A. PY - 2012 DA - 2012// TI - The translational landscape of mTOR signalling steers cancer initiation and metastasis JO - Nature VL - 485 ID - Hsieh2012 ER - TY - JOUR AU - Dubrovska, A. AU - Kim, S. AU - Salamone, R. J. AU - Walker, J. R. AU - Maira, S. M. AU - Garcia-Echeverria, C. PY - 2009 DA - 2009// TI - The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations JO - Proc Natl Acad Sci U S A VL - 106 ID - Dubrovska2009 ER - TY - JOUR AU - Guba, M. AU - Breitenbuch, P. AU - Steinbauer, M. AU - Koehl, G. AU - Flegel, S. AU - Hornung, M. PY - 2002 DA - 2002// TI - Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor JO - Nat Med VL - 8 ID - Guba2002 ER - TY - JOUR AU - McMenamin, M. E. AU - Soung, P. AU - Perera, S. AU - Kaplan, I. AU - Loda, M. AU - Sellers, W. R. PY - 1999 DA - 1999// TI - Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage JO - Cancer Res VL - 59 ID - McMenamin1999 ER - TY - JOUR AU - Troyer, D. A. AU - Jamaspishvili, T. AU - Wei, W. AU - Feng, Z. AU - Good, J. AU - Hawley, S. PY - 2015 DA - 2015// TI - A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer JO - Prostate VL - 75 ID - Troyer2015 ER - TY - JOUR AU - Meulenbeld, H. J. AU - Bono, J. S. AU - Tagawa, S. T. AU - Whang, Y. E. AU - Li, X. AU - Heath, K. H. PY - 2013 DA - 2013// TI - Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC) JO - Cancer Chemother Pharmacol VL - 72 ID - Meulenbeld2013 ER - TY - JOUR AU - Markman, B. AU - Tabernero, J. AU - Krop, I. AU - Shapiro, G. I. AU - Siu, L. AU - Chen, L. C. PY - 2012 DA - 2012// TI - Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors JO - Ann Oncol VL - 23 ID - Markman2012 ER - TY - JOUR AU - Nakabayashi, M. AU - Werner, L. AU - Courtney, K. D. AU - Buckle, G. AU - Oh, W. K. AU - Bubley, G. J. PY - 2012 DA - 2012// TI - Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer JO - BJU Int VL - 110 ID - Nakabayashi2012 ER - TY - JOUR AU - Templeton, A. J. AU - Dutoit, V. AU - Cathomas, R. AU - Rothermundt, C. AU - Bartschi, D. AU - Droge, C. PY - 2013 DA - 2013// TI - Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) JO - Eur Urol VL - 64 ID - Templeton2013 ER - TY - JOUR AU - Armstrong, A. J. AU - Shen, T. AU - Halabi, S. AU - Kemeny, G. AU - Bitting, R. L. AU - Kartcheske, P. PY - 2013 DA - 2013// TI - A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer JO - Clin Genitourin Cancer VL - 11 ID - Armstrong2013 ER - TY - JOUR AU - Bendell, J. C. AU - Rodon, J. AU - Burris, H. A. AU - Jonge, M. AU - Verweij, J. AU - Birle, D. PY - 2012 DA - 2012// TI - Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors JO - J Clin Oncol VL - 30 ID - Bendell2012 ER - TY - JOUR AU - Akinleye, A. AU - Avvaru, P. AU - Furqan, M. AU - Song, Y. AU - Liu, D. PY - 2013 DA - 2013// TI - Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics JO - J Hematol Oncol VL - 6 ID - Akinleye2013 ER - TY - JOUR AU - Sarbassov, D. D. AU - Ali, S. M. AU - Sengupta, S. AU - Sheen, J. H. AU - Hsu, P. P. AU - Bagley, A. F. PY - 2006 DA - 2006// TI - Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB JO - Mol Cell VL - 22 ID - Sarbassov2006 ER - TY - JOUR AU - Edlind, M. P. AU - Hsieh, A. C. PY - 2014 DA - 2014// TI - PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance JO - Asian J Androl VL - 16 ID - Edlind2014 ER - TY - JOUR AU - Traish, A. M. AU - Morgentaler, A. PY - 2009 DA - 2009// TI - Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth JO - Br J Cancer VL - 101 ID - Traish2009 ER - TY - JOUR AU - Berger, R. AU - Lin, D. I. AU - Nieto, M. AU - Sicinska, E. AU - Garraway, L. A. AU - Adams, H. PY - 2006 DA - 2006// TI - Androgen-dependent regulation of Her-2/neu in prostate cancer cells JO - Cancer Res VL - 66 ID - Berger2006 ER - TY - JOUR AU - Lee, M. S. AU - Igawa, T. AU - Yuan, T. C. AU - Zhang, X. Q. AU - Lin, F. F. AU - Lin, M. F. PY - 2003 DA - 2003// TI - ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells JO - Oncogene VL - 22 ID - Lee2003 ER - TY - JOUR AU - Neto, A. S. AU - Tobias-Machado, M. AU - Wroclawski, M. L. AU - Fonseca, F. L. AU - Teixeira, G. K. AU - Amarante, R. D. PY - 2010 DA - 2010// TI - Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis JO - J Urol VL - 184 ID - Neto2010 ER - TY - JOUR AU - Solit, D. B. AU - Rosen, N. PY - 2007 DA - 2007// TI - Targeting HER2 in prostate cancer: where to next? JO - J Clin Oncol VL - 25 ID - Solit2007 ER - TY - JOUR AU - Molife, L. R. AU - Omlin, A. AU - Jones, R. J. AU - Karavasilis, V. AU - Bloomfield, D. AU - Lumsden, G. PY - 2014 DA - 2014// TI - Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer JO - Future Oncol VL - 10 ID - Molife2014 ER - TY - JOUR AU - Liu, G. AU - Chen, Y. H. AU - Kolesar, J. AU - Huang, W. AU - Dipaola, R. AU - Pins, M. PY - 2013 DA - 2013// TI - Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer JO - Urol Oncol VL - 31 ID - Liu2013 ER - TY - JOUR AU - Whang, Y. E. AU - Armstrong, A. J. AU - Rathmell, W. K. AU - Godley, P. A. AU - Kim, W. Y. AU - Pruthi, R. S. PY - 2013 DA - 2013// TI - A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer JO - Urol Oncol VL - 31 ID - Whang2013 ER - TY - JOUR AU - Sridhar, S. S. AU - Hotte, S. J. AU - Chin, J. L. AU - Hudes, G. R. AU - Gregg, R. AU - Trachtenberg, J. PY - 2010 DA - 2010// TI - A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer JO - Am J Clin Oncol VL - 33 ID - Sridhar2010 ER - TY - JOUR AU - Ziada, A. AU - Barqawi, A. AU - Glode, L. M. AU - Varella-Garcia, M. AU - Crighton, F. AU - Majeski, S. PY - 2004 DA - 2004// TI - The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial JO - Prostate VL - 60 ID - Ziada2004 ER - TY - JOUR AU - Bono, J. S. AU - Bellmunt, J. AU - Attard, G. AU - Droz, J. P. AU - Miller, K. AU - Flechon, A. PY - 2007 DA - 2007// TI - Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer JO - J Clin Oncol VL - 25 ID - Bono2007 ER - TY - JOUR AU - Joshi, G. AU - Singh, P. K. AU - Negi, A. AU - Rana, A. AU - Singh, S. AU - Kumar, R. PY - 2015 DA - 2015// TI - Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents JO - Chem Biol Interact VL - 240 ID - Joshi2015 ER - TY - JOUR AU - Wu, J. D. AU - Haugk, K. AU - Woodke, L. AU - Nelson, P. AU - Coleman, I. AU - Plymate, S. R. PY - 2006 DA - 2006// TI - Interaction of IGF signaling and the androgen receptor in prostate cancer progression JO - J Cell Biochem VL - 99 ID - Wu2006 ER - TY - JOUR AU - Plymate, S. R. AU - Tennant, M. K. AU - Culp, S. H. AU - Woodke, L. AU - Marcelli, M. AU - Colman, I. PY - 2004 DA - 2004// TI - Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors JO - Prostate VL - 61 ID - Plymate2004 ER - TY - JOUR AU - Lin, H. K. AU - Yeh, S. AU - Kang, H. Y. AU - Chang, C. PY - 2001 DA - 2001// TI - Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor JO - Proc Natl Acad Sci U S A VL - 98 ID - Lin2001 ER - TY - JOUR AU - Cao, Y. AU - Nimptsch, K. AU - Shui, I. M. AU - Platz, E. A. AU - Wu, K. AU - Pollak, M. N. PY - 2015 DA - 2015// TI - Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer JO - Int J Cancer VL - 136 ID - Cao2015 ER - TY - JOUR AU - Stattin, P. AU - Rinaldi, S. AU - Biessy, C. AU - Stenman, U. H. AU - Hallmans, G. AU - Kaaks, R. PY - 2004 DA - 2004// TI - High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort JO - J Clin Oncol VL - 22 ID - Stattin2004 ER - TY - JOUR AU - Chan, J. M. AU - Stampfer, M. J. AU - Giovannucci, E. AU - Gann, P. H. AU - Ma, J. AU - Wilkinson, P. PY - 1998 DA - 1998// TI - Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study JO - Science VL - 279 ID - Chan1998 ER - TY - JOUR AU - Pollak, M. PY - 2000 DA - 2000// TI - Insulin-like growth factor physiology and cancer risk JO - Eur J Cancer VL - 36 ID - Pollak2000 ER - TY - JOUR AU - Yu, E. Y. AU - Li, H. AU - Higano, C. S. AU - Agarwal, N. AU - Pal, S. K. AU - Alva, A. PY - 2015 DA - 2015// TI - SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer JO - J Clin Oncol VL - 33 ID - Yu2015 ER - TY - JOUR AU - Hussain, M. AU - Rathkopf, D. AU - Liu, G. AU - Armstrong, A. AU - Kelly, W. K. AU - Ferrari, A. PY - 2015 DA - 2015// TI - A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer JO - Eur J Cancer VL - 51 ID - Hussain2015 ER - TY - JOUR AU - Adler, H. L. AU - McCurdy, M. A. AU - Kattan, M. W. AU - Timme, T. L. AU - Scardino, P. T. AU - Thompson, T. C. PY - 1999 DA - 1999// TI - Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma JO - J Urol VL - 161 ID - Adler1999 ER - TY - JOUR AU - Shariat, S. F. AU - Andrews, B. AU - Kattan, M. W. AU - Kim, J. AU - Wheeler, T. M. AU - Slawin, K. M. PY - 2001 DA - 2001// TI - Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis JO - Urology VL - 58 ID - Shariat2001 ER - TY - JOUR AU - Nakashima, J. AU - Tachibana, M. AU - Horiguchi, Y. AU - Oya, M. AU - Ohigashi, T. AU - Asakura, H. PY - 2000 DA - 2000// TI - Serum interleukin 6 as a prognostic factor in patients with prostate cancer JO - Clin Cancer Res VL - 6 ID - Nakashima2000 ER - TY - JOUR AU - George, D. J. AU - Halabi, S. AU - Shepard, T. F. AU - Sanford, B. AU - Vogelzang, N. J. AU - Small, E. J. PY - 2005 DA - 2005// TI - The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480 JO - Clin Cancer Res VL - 11 ID - George2005 ER - TY - JOUR AU - Zhu, M. L. AU - Kyprianou, N. PY - 2008 DA - 2008// TI - Androgen receptor and growth factor signaling cross-talk in prostate cancer cells JO - Endocr Relat Cancer VL - 15 ID - Zhu2008 ER - TY - JOUR AU - Aaronson, D. S. AU - Muller, M. AU - Neves, S. R. AU - Chung, W. C. AU - Jayaram, G. AU - Iyengar, R. PY - 2007 DA - 2007// TI - An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells JO - Mol Cell Endocrinol VL - 270 ID - Aaronson2007 ER - TY - JOUR AU - Karkera, J. AU - Steiner, H. AU - Li, W. AU - Skradski, V. AU - Moser, P. L. AU - Riethdorf, S. PY - 2011 DA - 2011// TI - The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study JO - Prostate VL - 71 ID - Karkera2011 ER - TY - JOUR AU - Hudes, G. AU - Tagawa, S. T. AU - Whang, Y. E. AU - Qi, M. AU - Qin, X. AU - Puchalski, T. A. PY - 2013 DA - 2013// TI - A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer JO - Investig New Drugs VL - 31 ID - Hudes2013 ER - TY - JOUR AU - Tannock, I. F. AU - Wit, R. AU - Berry, W. R. AU - Horti, J. AU - Pluzanska, A. AU - Chi, K. N. PY - 2004 DA - 2004// TI - Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer JO - N Engl J Med VL - 351 ID - Tannock2004 ER - TY - JOUR AU - Petrylak, D. P. AU - Tangen, C. M. AU - Hussain, M. H. AU - Lara, P. N. AU - Jones, J. A. AU - Taplin, M. E. PY - 2004 DA - 2004// TI - Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer JO - N Engl J Med VL - 351 ID - Petrylak2004 ER - TY - JOUR AU - Fizazi, K. AU - Bono, J. S. AU - Flechon, A. AU - Heidenreich, A. AU - Voog, E. AU - Davis, N. B. PY - 2012 DA - 2012// TI - Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer JO - Eur J Cancer VL - 48 ID - Fizazi2012 ER - TY - JOUR AU - Verras, M. AU - Sun, Z. PY - 2006 DA - 2006// TI - Roles and regulation of Wnt signaling and beta-catenin in prostate cancer JO - Cancer Lett VL - 237 ID - Verras2006 ER - TY - JOUR AU - Mulholland, D. J. AU - Cheng, H. AU - Reid, K. AU - Rennie, P. S. AU - Nelson, C. C. PY - 2002 DA - 2002// TI - The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli JO - J Biol Chem VL - 277 ID - Mulholland2002 ER - TY - JOUR AU - Truica, C. I. AU - Byers, S. AU - Gelmann, E. P. PY - 2000 DA - 2000// TI - Beta-catenin affects androgen receptor transcriptional activity and ligand specificity JO - Cancer Res VL - 60 ID - Truica2000 ER - TY - JOUR AU - Chesire, D. R. AU - Isaacs, W. B. PY - 2003 DA - 2003// TI - Beta-catenin signaling in prostate cancer: an early perspective JO - Endocr Relat Cancer VL - 10 ID - Chesire2003 ER - TY - JOUR AU - Yang, F. AU - Li, X. AU - Sharma, M. AU - Sasaki, C. Y. AU - Longo, D. L. AU - Lim, B. PY - 2002 DA - 2002// TI - Linking beta-catenin to androgen-signaling pathway JO - J Biol Chem VL - 277 ID - Yang2002 ER - TY - JOUR AU - Miyamoto, D. T. AU - Zheng, Y. AU - Wittner, B. S. AU - Lee, R. J. AU - Zhu, H. AU - Broderick, K. T. PY - 2015 DA - 2015// TI - RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance JO - Science VL - 349 ID - Miyamoto2015 ER - TY - JOUR AU - Lu, W. AU - Tinsley, H. N. AU - Keeton, A. AU - Qu, Z. AU - Piazza, G. A. AU - Li, Y. PY - 2009 DA - 2009// TI - Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation JO - Eur J Pharmacol VL - 602 ID - Lu2009 ER - TY - JOUR AU - Smith, M. R. AU - Manola, J. AU - Kaufman, D. S. AU - Oh, W. K. AU - Bubley, G. J. AU - Kantoff, P. W. PY - 2006 DA - 2006// TI - Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy JO - J Clin Oncol VL - 24 ID - Smith2006 ER -